← Back to Search

Monoclonal Antibodies

24 µg/kg LY3471851 for Atopic Dermatitis

Phase 1
Waitlist Available
Research Sponsored by Nektar Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up postdose on day 1 through day 14
Awards & highlights

Study Summary

This trial is testing an injection for eczema that is given under the skin. The study will last up to 48 weeks and include up to 23 visits to a study center.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~postdose on day 1 through day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and postdose on day 1 through day 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: Maximum Concentration (Cmax) of LY3471851
PK: Trough Concentrations (Ctrough) of LY3471851
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3471851

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: 24 µg/kg LY3471851Active Control1 Intervention
Participants received subcutaneous injection of 24 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
Group II: 10 µg/kg LY3471851Active Control1 Intervention
Participants received subcutaneous (SC) injection of 10 microgram per kilogram (μg/kg) LY3471851 every 2 weeks for a treatment period of 12 weeks.
Group III: 12 µg/kg LY3471851Active Control1 Intervention
Participants received subcutaneous injection of 12 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
Group IV: PlaceboPlacebo Group1 Intervention
Participants received subcutaneous injection of placebo every 2 weeks for a treatment period of 12 weeks.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyIndustry Sponsor
2,610 Previous Clinical Trials
3,200,379 Total Patients Enrolled
Nektar TherapeuticsLead Sponsor
58 Previous Clinical Trials
10,294 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,342 Previous Clinical Trials
404,702 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of LY3471851 in Participants With Eczema
2019. "A Study of LY3471851 in Participants With Eczema". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04081350.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top